Drugs / Argon
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05482945 | May 2022 → Mar 2026 overdue | cardiac arrest | Mario Negri Institute for Pharmacological Research | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07200180 | Sep 2025 → Oct 2026 expected | carotid stenosis | Negovsky Reanimatology Research Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Argon | “Argon, in contrast, is accessible, safe, and technologically straightforward to administer.” NCT07200180 ↗ |
| Modality | Other / unclassified | “Noble gas Argon” NCT05482945 ↗ |
| Route | Inhaled | “post-resuscitation ventilation with a 70/30 argon/oxygen (Ar/O2) gas mixture” PMID 41079544 ↗ Sep 2025 |